Q4 2025 Cibus Inc Earnings Call Transcript
Key Points
- Cibus Inc (CBUS) has secured seven rice customers, representing over $200 million in potential annual royalty opportunities.
- The company received its first customer payment from its sustainable ingredients program, indicating progress in commercialization.
- Cibus Inc (CBUS) was selected by the UK government as a technology partner for its farming innovation program, showcasing its industry leadership.
- The EU reached a political agreement on new genomic techniques legislation, which Cibus Inc (CBUS) has been helping to shape, opening up significant market opportunities.
- The company has made significant advancements in gene editing technology, allowing for predictable trait development within 12 to 15 months, enhancing its appeal to seed companies.
- Cibus Inc (CBUS) reported a net loss of $31.9 million for the fourth quarter, an increase from the previous year's loss of $25.8 million.
- The company's cash and cash equivalents were $9.9 million as of December 31, 2025, indicating a need for careful financial management.
- Despite progress, commercialization in key markets like India is not expected until closer to 2030, delaying potential revenue streams.
- The company is reliant on regulatory developments, such as the EU's genomic techniques legislation, which can be unpredictable and impact market access.
- Cibus Inc (CBUS) has implemented cost-saving initiatives, including workforce reductions, which may impact operational capacity and morale.
Good afternoon, and welcome to the Cibus fourth quarter 2025 results conference call. (Operator Instructions) Please also note today's event is being recorded. At this time, I'd like to turn the conference over to Carlo Broos, Chief Financial Officer. Sir, please go ahead.
Thank you, and good afternoon. I'd like to thank you for taking time to join us for Cibus' fourth quarter 2025 financial results and business update conference call and webcast. Presenting with me today is Peter Beetham, Co-Founder, Interim Chief Executive Officer, President and COO; and Greg Gocal, Co-Founder and our Chief Scientific Officer.
Before we begin the call, I'd like to remind everyone that statements made on the call and webcast, including those regarding future financial results and future operational goals and industry prospects are forward-looking and may be subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the call. Please refer to Cibus' SEC
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
